Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Cancer Discov. 2018 Mar 6;8(5):582–599. doi: 10.1158/2159-8290.CD-16-0861

Figure 6.

Figure 6

TEAD4 is overexpressed in high-risk neuroblastoma tumors. (A) Expression of TEAD4 across high risk and stage 1 subtypes (B) VIPER transcriptional activity of TEAD4 across high risk and Stage 1 subtypes. (C) Histogram of primary neuroblastoma samples stained for TEAD4 protein by immunohistochemistry on a tissue microarray, segregated by risk level and (D) MYCN-amplification status in high-risk neuroblastoma, showing differential pattern of TEAD4 protein staining intensity (where 0=no staining; 1=low staining; 2=moderate staining; 3=high staining). See also Supplementary Table S8.